2022
Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS
Shapiro A, Kushnir V, Seifer D. Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS. 2022, 511-525. DOI: 10.1007/978-3-030-92589-5_25.Peer-Reviewed Original ResearchPolycystic ovary syndromeAnti-Mullerian hormonePathophysiology of PCOSSerum anti-Mullerian hormoneElevated AMH levelsAvailable treatment modalitiesNovel therapeutic approachesFuture therapeutic targetsChronic anovulationOvulatory dysfunctionAMH levelsOvary syndromeOvulatory functionTreatment modalitiesNormal folliculogenesisTherapeutic approachesTherapeutic targetPatientsCritical roleAnovulationDysfunctionPathophysiologySyndromeFolliculogenesisHormone
2020
8. Level of Anti-Müllerian Hormone and the Association of Vitamin D Deficiency with Polycystic Ovarian Syndrome in Adolescent Females
Simpson S, Seifer D, Shabanova V, Lynn A, Howe C, Rowe E, Caprio S, Vash-Margita A. 8. Level of Anti-Müllerian Hormone and the Association of Vitamin D Deficiency with Polycystic Ovarian Syndrome in Adolescent Females. Journal Of Pediatric And Adolescent Gynecology 2020, 33: 241-242. DOI: 10.1016/j.jpag.2020.01.067.Peer-Reviewed Original Research
2012
Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation
Tal R, Seifer D, Shohat-Tal A, Grazi R, Malter H. Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation. Fertility And Sterility 2012, 98: s84. DOI: 10.1016/j.fertnstert.2012.07.304.Peer-Reviewed Original Research
2007
Serum müllerian-inhibiting substance in Down's syndrome pregnancies
Seifer DB, MacLaughlin DT, Cuckle HS. Serum müllerian-inhibiting substance in Down's syndrome pregnancies. Human Reproduction 2007, 22: 1017-1020. PMID: 17218369, DOI: 10.1093/humrep/del497.Peer-Reviewed Original ResearchConceptsDown syndrome pregnanciesMüllerian-inhibiting substanceSyndrome pregnanciesUnaffected pregnanciesPregnancy-associated plasma proteinMI levelsMaternal serum levelsSerum MIS levelsWeeks of gestationCase-control studyAntenatal screening programmeAssisted reproduction techniquesMedian valueSerum levelsMIS levelsMaternal ageScreening programPregnancyDown syndromeUnaffected controlsReproduction techniquesSignificant correlationSyndromePlasma proteinsSerum
2005
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses
1985
Heparin-Induced Thrombocytopenia and Thrombosis: Detection and Specificity of a Platelet-Aggregating IgG
Sandler R, Seifer D, Morgan K, Pockros P, Wypych J, Weiss L, Schiffman S. Heparin-Induced Thrombocytopenia and Thrombosis: Detection and Specificity of a Platelet-Aggregating IgG. American Journal Of Clinical Pathology 1985, 83: 760-764. PMID: 4003343, DOI: 10.1093/ajcp/83.6.760.Peer-Reviewed Original ResearchConceptsMultiple arterial occlusionsResult of thrombocytopeniaHeparin-Induced ThrombocytopeniaSamples of serumPlatelet-aggregating factorCatastrophic syndromeWorst sequelaeAntithrombotic therapyHeparin therapyArterial occlusionArterial thrombosisIgG productionPresence of heparinNormal plateletsPlasma samplesHeparinThrombocytopeniaFurther studiesThrombosisTherapyIgGSequelaeSepticemiaSyndromeWater intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report.
Seifer DB, Sandberg EC, Ueland K, Sladen RN. Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. The Journal Of Reproductive Medicine 1985, 30: 225-8. PMID: 3923190.Peer-Reviewed Original ResearchConceptsOxytocin nasal sprayNasal sprayWater intoxicationGuillain-Barré typeSevere water intoxicationGuillain-Barré syndromeHyponatremic encephalopathyPeripheral polyneuritisInappropriate secretionNeurologic manifestationsSame hospitalizationViral illnessBreast feedIntravenous fluidsCase reportNursing womenNursing mothersAntidiuretic hormoneUnmonitored useTemporal associationPatientsConvulsionsSyndromeWork daysIntoxication